logo image
search icon
Global COVID-19 Therapeutics Market

COVID-19 Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, Others (anti-inflammatory drugs, convalescent plasma, others)), By Region, And By Segment Forecasts, 2023-2031.

Report ID : 1184 | Published : 2024-03-15 | Pages: 190 | Format: PDF/EXCEL

The COVID-19 Therapeutics Market is expected to grow at a -15.0 % CAGR during the forecast period for 2023-2031.

COVID-19 Therapeutics Market

The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the expansion of the COVID-19 therapeutics market during the forecast period. According to the World Health Organization (WHO), globally, 175,847,347 confirmed cases of COVID-19, including 3,807,276 deaths, were reported to WHO as of 15 June 2021. Covid-19 cases are increasing day by day, and there is no officially approved drug for COVID-19. Many countries are facing a shortage of drugs likely to offer growth opportunities for pharmaceutical drug manufacturers. Leading market players are also developing innovative and efficient covid-19 drug therapies, resulting in overall market growth. 

Major factors responsible for the growth of the COVID 19 therapeutic market are the fast adoption of advanced technologies, the growing number of corona patients, increasing healthcare expenditures, rising awareness about coronavirus, and increasing efforts by the pharmaceutical companies to develop covid-19 therapeutic drugs. For instance, Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 treatments at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Furthermore, increasing research investments for the R&D of covid-19 therapeutic drugs is anticipated to drive market growth in the future. However, the high cost required to validate therapies, and long-term clinical trials limit the COVID-19 therapeutics market growth.

 Market Segmetation

The COVID-19 therapeutics market can be segmented into Drug Class, and Region. By Drug Claas, the market can be divided into Corticosteroids (Dexamethasone, Hydrocortisone, Methylprednisolone, Others (Prednisone, Others)), Anti-viral (Remdesivir, Nirmatrelvir, Others (Ivermectin, Others)), Monoclonal Antibodies (Sotrovimab, Casirivimab plus imdevimab, Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others), Kinase Inhibitors (Baricitinib, Others (Tofacitinib, Others)),Others (anti-inflammatory drugs, convalescent plasma, others). Regionally, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the COVID-19 therapeutics market in the coming future.

Competitive Landscape

Some major key players in the COVID-19 Therapeutics Market:

  • AstraZeneca plc,
  • Celltrion Healthcare Co.,Ltd,
  • Pfizer Inc.,
  • Ridgeback Biotherapeutics,
  • Merck & Co.,
  • Veru Inc.,
  • Gilead Sciences, Inc.,
  • GSK plc,
  • Shionogi & Company, Limited,
  • NRx Pharmaceuticals, Inc.,
  • Kintor Pharma-B,
  • Regeneron Pharmaceuticals,
  • CytoDyn,
  • Atea Pharmaceuticals, Inc.,
  • Amarin Corporation,
  • APEIRON Biologics AG,
  • Abivax SA,
  • Alexion Pharmaceuticals,
  • Bellerophon Therapeutics,
  • Blade Therapeutics, Inc,
  • Roivant Sciences,
  • Synairgen,
  • Sorrento Therapeutics,
  • Fulcrum Therapeutics,
  • Ono Pharmaceutical Co., Ltd.,
  • Revive Therapeutics Ltd.,
  • other prominent players

The COVID-19 Therapeutics Market Report Scope

Report Attribute

Specifications

Growth Rate CAGR

CAGR of -15.0 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Billion and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Drug Class

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

AstraZeneca plc, Celltrion Healthcare Co.,Ltd, Pfizer Inc., Ridgeback Biotherapeutics, Merck & Co., Veru Inc., Gilead Sciences, Inc., GSK plc, Shionogi & Company, Limited, NRx Pharmaceuticals, Inc., Kintor Pharma-B, Regeneron Pharmaceuticals, CytoDyn, Atea Pharmaceuticals, Inc., Amarin Corporation, APEIRON Biologics AG, Abivax SA, Alexion Pharmaceuticals, Bellerophon Therapeutics, Blade Therapeutics, Inc, Roivant Sciences, Synairgen, Sorrento Therapeutics, Fulcrum Therapeutics, Ono Pharmaceutical Co., Ltd., Revive Therapeutics Ltd., and other prominent players

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global COVID-19 Therapeutics Market Snapshot

Chapter 4. Global COVID-19 Therapeutics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

4.9. Clinical Trial Analysis/Pipeline Analysis 2022

Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis

5.1. By Drug Class & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Drug Class:

5.2.1. Corticosteroids

5.2.1.1. Dexamethasone

5.2.1.2. Hydrocortisone

5.2.1.3. Methylprednisolone

5.2.1.4. Others (Prednisone, Others)

5.2.2. Anti-viral

5.2.2.1. Remdesivir

5.2.2.2. Nirmatrelvir

5.2.2.3. Others (Ivermectin, Others)

5.2.3. Monoclonal Antibodies

5.2.3.1. Sotrovimab

5.2.3.2. Casirivimab plus imdevimab

5.2.3.3. Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others)

5.2.4. Kinase Inhibitors

5.2.4.1. Baricitinib

5.2.4.2. Others (Tofacitinib, Others)

5.2.5. Others (anti-inflammatory drugs, convalescent plasma, others)

Chapter 6. COVID-19 Therapeutics Market Segmentation 2: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts By Drug Class, 2022-2030

6.1.2. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2022-2030

6.2. Europe

6.2.1. Europe COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2022-2030

6.2.2. Europe COVID-19 Therapeutics Market revenue (US$ Million) by country, 2022-2030

6.3. Asia Pacific

6.3.1. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2022-2030

6.3.2. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) by country, 2022-2030

6.4. Latin America

6.4.1. Latin America COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2022-2030

6.4.2. Latin America COVID-19 Therapeutics Market revenue (US$ Million) by country, 2022-2030

6.5. Middle East & Africa

6.5.1. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2022-2030

6.5.2. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) by country, 2022-2030

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. AstraZeneca plc

7.2.2. Celltrion Healthcare Co.,Ltd

7.2.3. Pfizer Inc.

7.2.4. Ridgeback Biotherapeutics

7.2.5. Merck & Co.

7.2.6. Veru Inc.

7.2.7. Gilead Sciences, Inc.

7.2.8. GSK plc

7.2.9. Shionogi & Company, Limited

7.2.10. NRx Pharmaceuticals, Inc.

7.2.11. Kintor Pharma-B

7.2.12. Regeneron Pharmaceuticals

7.2.13. CytoDyn

7.2.14. Atea Pharmaceuticals, Inc.

7.2.15. Amarin Corporation

7.2.16. APEIRON Biologics AG

7.2.17. Abivax SA

7.2.18. Alexion Pharmaceuticals

7.2.19. Bellerophon Therapeutics

7.2.20. Blade Therapeutics, Inc

7.2.21. Roivant Sciences

7.2.22. Synairgen

7.2.23. Sorrento Therapeutics

7.2.24. Fulcrum Therapeutics

7.2.25. Ono Pharmaceutical Co., Ltd.

7.2.26. Revive Therapeutics Ltd.

7.2.27. Eli Lilly and Company

7.2.28. Other Prominent Players

Market Segmentation of COVID-19 Therapeutics Market 

Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 202 to 2030 based on Drug Class

  • Corticosteroids
    • Dexamethasone
    • Hydrocortisone
    • Methylprednisolone
    • Others (Prednisone, Others)
  • Anti-viral
    • Remdesivir
    • Nirmatrelvir
    • Others (Ivermectin, Others)
  • Monoclonal Antibodies
    • Sotrovimab
    • Casirivimab plus imdevimab
    • Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others)
  • Kinase Inhibitors
    • Baricitinib
    • Others (Tofacitinib, Others)
  • Others (anti-inflammatory drugs, convalescent plasma, others)

COVID-19 Therapeutics Market

Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • U.S.
  • Canada

Europe COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

The Middle East & Africa COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

 Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

 

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

 

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

 

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

Who are the Key Players in the Global COVID-19 Therapeutics Market?

The COVID-19 Therapeutics Market is expected to grow at a -15.0 % CAGR during the forecast period for 2023-2031.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$5700
$7786
$11886
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach